COMP <GO>
BHC vs JNJ // ENTERPRISE SCALE & MARKET CAP
Bausch Health Companies Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BHC 6
— JNJ 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $8.02 (-2.19%) • MKT CAP: $3.07B
market-cap
$3.07B
LAST: $270.56 (-0.97%) • MKT CAP: $657.68B
market-cap
$657.68B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.60% | 25.50% | -17.90 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.5x | 18.5x | -8.00 | BHC | /valuation <GO> |
| Free Cash Flow Yield | 22.00% | 2.97% | +19.03 | BHC | /fcf-yield <GO> |
| Operating Margin | 17.70% | 34.70% | -17.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.50% | 28.50% | -27.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 6.00% | +0.70 | BHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | BHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.8 | 59.1 | +5.70 | BHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.7x | 23.0x | -3.30 | BHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $3.07B | $657.68B | -$654.61B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BHC REV | JNJ REV | BHC GROSS % | JNJ GROSS % | BHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $10.27B | $94.19B | — | 67.9% | $1.00B | $19.70B |
| FY 2024 | $9.63B | $88.82B | — | 69.1% | $1.26B | $19.84B |
| FY 2023 | $8.76B | $85.16B | — | — | $637.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BHC // BETA 0.97
JNJ // BETA 1.08